S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in
NASDAQ:ENDP

Endo International Stock Forecast, Price & News

$7.93
-1.38 (-14.82 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.78
Now: $7.93
$9.14
50-Day Range
$6.81
MA: $8.26
$10.55
52-Week Range
$2.08
Now: $7.93
$10.89
Volume8.99 million shs
Average Volume4.48 million shs
Market Capitalization$1.83 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; TESTOPEL for TRT in conditions associated with a deficiency or absence of endogenous testosterone; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; VOLTAREN gel for the relief of joint pain of osteoarthritis; LIDODERM for the relief of pain; TESTOPEL, an implantable pellet indicated for TRT in conditions; EDEX to treat erectile dysfunction; and LIDODERM a topical patch product containing lidocaine. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays; and products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
Endo International logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ENDP
CUSIP29264F20
Phone011-353-1268-2000
Employees3,172
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.91 billion
Cash Flow$5.75 per share
Book Value($3.82) per share

Profitability

Net Income$-422,640,000.00

Miscellaneous

Market Cap$1.83 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.40 out of 5 stars

Medical Sector

569th out of 1,960 stocks

Pharmaceutical Preparations Industry

276th out of 771 stocks

Analyst Opinion: 1.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
$7.93
-1.38 (-14.82 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ENDP News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Endo International (NASDAQ:ENDP) Frequently Asked Questions

Is Endo International a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 2 sell ratings, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Endo International stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENDP, but not buy additional shares or sell existing shares.
View analyst ratings for Endo International
or view top-rated stocks.

What stocks does MarketBeat like better than Endo International?

Wall Street analysts have given Endo International a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Endo International wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Endo International's next earnings date?

Endo International is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Endo International
.

How were Endo International's earnings last quarter?

Endo International plc (NASDAQ:ENDP) announced its quarterly earnings data on Thursday, February, 25th. The company reported $0.75 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.48 by $0.27. Endo International had a negative net margin of 5.30% and a negative trailing twelve-month return on equity of 85.80%. During the same quarter last year, the company posted $0.74 EPS.
View Endo International's earnings history
.

How has Endo International's stock been impacted by Coronavirus?

Endo International's stock was trading at $3.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ENDP shares have increased by 103.9% and is now trading at $7.93.
View which stocks have been most impacted by COVID-19
.

What guidance has Endo International issued on next quarter's earnings?

Endo International updated its FY21 earnings guidance on Thursday, February, 25th. The company provided earnings per share guidance of $1.80-2.30 for the period, compared to the Thomson Reuters consensus estimate of $2.32. The company issued revenue guidance of $2.55-2.79 billion, compared to the consensus revenue estimate of $2.77 billion.

What price target have analysts set for ENDP?

7 brokerages have issued 1 year price targets for Endo International's stock. Their forecasts range from $3.00 to $12.00. On average, they expect Endo International's share price to reach $6.80 in the next year. This suggests that the stock has a possible downside of 14.2%.
View analysts' price targets for Endo International
or view top-rated stocks among Wall Street analysts.

Who are Endo International's key executives?

Endo International's management team includes the following people:
  • Mr. Blaise Coleman, Pres, CEO & Director (Age 47, Pay $1.9M)
  • Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 49, Pay $1.82M)
  • Mr. Patrick A. Barry, Exec. VP & Pres of Global Commercial Operations (Age 53, Pay $1.47M)
  • Mr. Mark T. Bradley, Exec. VP & CFO
  • Mr. Robert Polke, Exec. VP & Global Head of Operations
  • Mr. Jack D. Boyle, Sr. VP, Controller & Chief Accounting Officer (Age 45)
  • Ms. Ruth Thorpe, Sr. VP of Information Technology & Chief Information Officer
  • Ms. Laure E. Park, Sr. VP of Investor Relations & Corp. Affairs
  • Ms. Susan Williamson, Sr. VP & Chief Compliance Officer
  • Ms. Tracy Basso, Chief HR Officer

What is Paul Campanelli's approval rating as Endo International's CEO?

25 employees have rated Endo International CEO Paul Campanelli on Glassdoor.com. Paul Campanelli has an approval rating of 86% among Endo International's employees.

Who are some of Endo International's key competitors?

What other stocks do shareholders of Endo International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Endo International investors own include Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Mallinckrodt (MNK), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Micron Technology (MU), Cleveland-Cliffs (CLF), Pfizer (PFE), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

What is Endo International's stock symbol?

Endo International trades on the NASDAQ under the ticker symbol "ENDP."

Who are Endo International's major shareholders?

Endo International's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (0.99%), Rhumbline Advisers (0.26%), New York State Teachers Retirement System (0.14%), Russell Investments Group Ltd. (0.13%), Hunter Associates Investment Management LLC (0.08%) and Jackson Creek Investment Advisors LLC (0.08%). Company insiders that own Endo International stock include International Plc Endo and Roger H Kimmel.
View institutional ownership trends for Endo International
.

Which major investors are selling Endo International stock?

ENDP stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Bank of New York Mellon Corp, American International Group Inc., Dupont Capital Management Corp, and Arizona State Retirement System.
View insider buying and selling activity for Endo International
or view top insider-selling stocks.

Which major investors are buying Endo International stock?

ENDP stock was purchased by a variety of institutional investors in the last quarter, including Jackson Creek Investment Advisors LLC, Rhumbline Advisers, Alpha Paradigm Partners LLC, Hunter Associates Investment Management LLC, IFP Advisors Inc, Vantage Consulting Group Inc, Nisa Investment Advisors LLC, and Oregon Public Employees Retirement Fund.
View insider buying and selling activity for Endo International
or or view top insider-buying stocks.

How do I buy shares of Endo International?

Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Endo International's stock price today?

One share of ENDP stock can currently be purchased for approximately $7.93.

How much money does Endo International make?

Endo International has a market capitalization of $1.83 billion and generates $2.91 billion in revenue each year. The company earns $-422,640,000.00 in net income (profit) each year or $2.38 on an earnings per share basis.

How many employees does Endo International have?

Endo International employs 3,172 workers across the globe.

What is Endo International's official website?

The official website for Endo International is www.endo.com.

Where are Endo International's headquarters?

Endo International is headquartered at First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355.

How can I contact Endo International?

Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]


This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.